#CNBC The market reaction is overdone on Viking Therapeutics, says BTIG’s Justin Zelin
The market reaction is overdone on Viking Therapeutics, says BTIG’s Justin Zelin
Justin Zelin, BTIG senior biotech analyst, joins ‘The Exchange’ to discuss GLP-1’s and the share decline for Viking Therapeutics and why he’s still bullish the stock.
Thank you for your support in keeping this website running.💛
View on “Tokyo Trend News”
#MILENIO
コメントを送信